Journal Information
Vol. 103. Issue S2.
Actualización del uso de ustekinumab: un ava nce en el tratamiento de la psoriasis
Pages 39-44 (October 2012)
Share
Share
Download PDF
More article options
Vol. 103. Issue S2.
Actualización del uso de ustekinumab: un ava nce en el tratamiento de la psoriasis
Pages 39-44 (October 2012)
Full text access
Ustekinumab. Neoplasias y otros aspectos de seguridad
Ustekinumab. Neoplasms and Other Safety Aspects
Visits
4248
J. Santos-Juanes
Corresponding author
jorgesantosjuanes@gmail.com

Autor para correspondencia.
, P. Coto, C. Galache
Servicio de Dermatología II. Hospital Universitario Central de Asturias. Asturias. España
This item has received
Article information
Resumen

La reciente aparición de nuevos tratamientos biológicos ha permitido un importante avance en el control de la psoriasis. Las interleucinas 12 y 23 desempeñan un papel importante en el control de neoplasias e infecciones. La aparición de nuevas moléculas que bloquean su acción ha reavivado el debate sobre el riesgo de desarrollar neoplasias en los pacientes con psoriasis que reciben este tipo de medicaciones.

En este artículo, realizamos una revisión de los estudios de seguridad a tres y cuatro años disponibles hasta la fecha y una revisión de la literatura.

Con los datos actuales, se puede concluir que los pacientes expuestos a ustekinumab no presentan mayor riesgo de padecer neoplasias que la población general.

Palabras clave:
Ustekinumab
Seguridad
Abstract

The recent introduction of a new class of biologic agents in psoriasis has led to important advances in the management of this disease. IL-12 and IL-23 play a key role in the control of malignancies and infections. The development of novel molecules capable of blocking the action of these cytokines has rekindled the debate on whether biologic agents increase the risk of malignancy in patients with psoriasis.

In this chapter, we review the safety data for patients who have been treated for 3 or 4 years and the literature on the use of ustekinumab.

Based on the available evidence, it can be concluded that patients treated with stekinumab do not have a higher risk of malignancy than the general population.

Keywords:
Ustekinumab
Safety
Full text is only aviable in PDF
Bibliografía
[1.]
G. Krueger, J. Koo, M. Lebwohl, A. Menter, R.S. Stern, T. Rolstad.
The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey.
Arch Dermatol, 137 (2001), pp. 280-284
[2.]
A. Blauvelt.
T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis.
J Invest Dermatol, 128 (2008), pp. 1064-1067
[3.]
J.L. Langowski, X. Zhang, L. Wu, J.D. Mattson, T. Chen, K. Smith, et al.
IL-23 promotes tumor incidence and growth.
Nature, 442 (2006), pp. 461-465
[4.]
M.J. Smyth, M. Taniguchi, S.E. Street.
The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent.
J Immunol, 165 (2000), pp. 2665-2670
[5.]
X. Shu, J. Ji, J. Sundquist, K. Sundquist, K. Hemminki.
Survival in cancer patients hospitalized for psoriasis: a population-based cohort study in Sweden.
Br J Dermatol, 165 (2011), pp. 129-136
[6.]
J.M. Gelfand, D.B. Shin, A.L. Neimann, X. Wang, D.J. Margolis, A.B. Troxel.
The risk of lymphoma in patients with psoriasis.
J Invest Dermatol, 126 (2006), pp. 2194-2201
[7.]
Y.J. Chen, C.Y. Wu, T.J. Chen, J.L. Shen, S.Y. Chu, C.B. Wang, et al.
The risk of cancer in patients with psoriasis: a population-based cohort study in Taiwan.
J Am Acad Dermatol, 65 (2011), pp. 84-91
[8.]
Y.B. Brauchli, S.S. Jick, M. Miret, C.R. Meier.
Psoriasis and risk of incident cancer: an inception cohort study with a nested casecontrol analysis.
J Invest Dermatol, 129 (2009), pp. 2604-2612
[9.]
C.F. Paul, P.A. Gourraud.
Cancer risk evaluation in psoriasis: in search of the Holy Grail?.
J Invest Dermatol, 129 (2009), pp. 2547-2549
[10.]
Y. Benjamini, Y. Hochberg.
Controlling the false discovery rate: a practical and powerful approach to multiple testing.
J Roy Statist Soc B, 57 (1995), pp. 125-133
[11.]
J.D. Lewis, C. Brensinger.
Agreement between GPRD smoking data: a survey of general practitioners and a population-based survey.
Pharmacoepidemiol Drug Saf, 13 (2004), pp. 437-441
[12.]
K. Papp, V. Ho, N. Yeilding, P.O. Szapary, M.C. Hsu, Y. Poulin, et al.
Malignancies in Ustekinumab-treated moderate-to-severe psoriasis patients: observations with up to 3 years of follow-up and comparisons to the general United States Population.
Poster. EADV. Gotemburgo, (2010), pp. 6-10
[13.]
K. Reich, C. Leonardi, C.E.M. Griffiths, P.O. Szapary, Y. Wasfi, M.C. Hsu, on behalf of the Phoenix 1 and 2 and ACCEPT investigators, et al.
Update of the cumulative safety experience of ustekinumab: results from the ustekinumab psoriasis clinical development program with up to 4 years of follow-up. Comunicación oral. Presentation at world congress of Derm 2011.
Seúl, (2011),
[14.]
A.I. Rubin, E.H. Chen, D. Ratner.
Basal-cell carcinoma.
N Engl J Med, 353 (2005), pp. 2262-2269
[15.]
C.L. Leonardi, A.B. Kimball, K.A. Papp, N. Yeilding, C. Guzzo, Y. Wang, et al.
PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1).
Lancet, 371 (2008), pp. 1665-1674
[16.]
Bissonnette R, Lambert J, Yeilding N, Szapary P, Hsu MC, Rizova E. Effect of ustekinumab on Commonly Measured Laboratory Parameters: three year results from the PHOENIX 1 Clinical Trial. Poster. Congress of the Psoriasis International Network. Paris, 1–4 Jul 2010.
[17.]
A. Menter, A. Gottlieb, S.R. Feldman, A.S. Van Voorhees, C.L. Leonardi, K.B. Gordon, et al.
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.
J Am Acad Dermatol, 58 (2008), pp. 826-850
[18.]
A.B. Kimball, D. Gladman, J.M. Gelfand, K. Gordon, E.J. Horn, N.J. Korman, et al.
National Psoriasis Foundation. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening.
J Am Acad Dermatol, 58 (2008), pp. 1031-1042
[19.]
D. Pathirana, A.D. Ormerod, P. Saiag, C. Smith, P.I. Spuls, A. Nast, et al.
European S3-guidelines on the systemic treatment of psoriasis vulgaris.
J Eur Acad Dermatol Venereol, 23 (2009), pp. 1-70
[20.]
K.A. Papp, R.G. Langley, M. Lebwohl, G.G. Krueger, P. Szapary, N. Yeilding, et al.
PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 2).
Lancet, 371 (2008), pp. 1675-1684
[21.]
E.J. Scherl, S. Kumar, R.U. Warren.
Review of the safety and efficacy of ustekinumab.
Therap Adv Gastroenterol, 3 (2010), pp. 321-328
[22.]
B.M. Segal, C.S. Constantinescu, A. Raychaudhuri, L. Kim, R. Fidelus-Gort, L.H. Kasper, Ustekinumab MS Investigators.
Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.
Lancet Neurol, 7 (2008), pp. 796-804
Copyright © 2012. Academia Española de Dermatología y Venereología
Download PDF
Idiomas
Actas Dermo-Sifiliográficas
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?